NCT07353294 2026-04-22
Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 1 Enrolling by invitation
Clinical Trials
8 trialsNCT07517419 2026-04-08
PIPAC in Gastric Peritoneal Metastasis
Chinese University of Hong Kong
Phase 2 Enrolling by invitation
NCT07139951 2025-12-31
HORIZON
Mayo Clinic
Phase 2 Enrolling by invitation
NCT07312578 2025-12-31
Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma
Peking University
Phase 2 Enrolling by invitation
NCT06786780 2025-03-26
ECCO
Chongqing University Cancer Hospital
Phase 2 Enrolling by invitation
NCT06755515 2025-01-01
A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer
Shandong New Time Pharmaceutical Co., LTD
Phase 2/3 Enrolling by invitation
NCT06048926 2023-09-21
Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital with Nanjing Medical University
Phase NA Enrolling by invitation
NCT04762459 2022-02-24
APEX
ChineseAMS
Phase 3 Enrolling by invitation